Member Info for dippfs

Doc 83 if we have a trial lined up then it would be formally announced by RNS. Unless there is a slip of the tongue they wouldn’t usually announce things like this at the AGM. Having said that I do plan to attend if the timings allow as the BOD need to be held to account for the disastrous share price performance.

JR90 you miss the point.If Infla RX gets adopted as standard of care which presumably it will now it has an EUA - then the placebo arm of any new trial is going to perform 20% better. So suddenly the bar is going to be higher for any new trial Synairgen does. Synairgen have already botched 1 trial due to improvements in standard of care - all im saying is lets hope they are keeping an eye on this and taking it into consideration in any new trial designs.

Infla RX is interesting. EUA based on a 700 patient trial and had a statistically significant result in death reduction by 20%. Just shows how agonisingly close sprinter was. Well the good news for SNG is now this is authorised presumably the standard of care for the endpoint were going to go for just got 20% better ! Lets hope SNG dont make the same mistake twice and take this development into consideration when planning any new trial.

The parallels to Sirius Minerals are uncanny. Fantastic product but not enough cash to take it the next level and a collapsing share price. Lets hope we dont have the same end result.

What are the rumours from the AZ camp please ?

The trial will be initiated across 10 sites in the UK and seek to enrol 1000 patients, where 1000 test positive for respiratory viral infection, over a 12-month period.

Above pasted from the universal trial RNS. Trial runs over 12 months and 1st patient enrolled 1st September. Although as has already pointed out it’s not a blinded trial so we should have some data on this already.

But if they are using this universal trial to inform future trials then we could end up being made to wait until after September before we see a new trial ?

I literally have no idea, the truth is we don’t have a clue what is going on.

I wouldn’t pin anything on the official date of winter ending or whatever. The company try their best to give rough timescales but they’ll maybe they will hit them or maybe they won’t. Personally I don’t expect an update until there is something to update. Worst case scenario we will have to wait for the AGM / year end accounts which is May where we should get a full progress update. My own personal plan is to suck it up until then and review the situation based on the update. If we get news before then, it’s a bonus. Now a lot else we can do I don’t think.

I thought someone on this forum said recently that the second agent was pretty much done and currently with the regulators for final sign off ?

Synairgen had 27M of cash in the interims, and they stated this was enough to last through to AT LEAST September. But this years expenditure will be WAY lower than the 18M burnt in 2021 because we dont have the huge expense of running a trial currently. We wont know for sure until the next set of accounts, but I suspect our current overheads are probably quite low and we might be able to crawl along for a couple of years before we need to do a raise.

Last years AGM was June 30th so it’s only a couple of months away in any case. We have waited this long might as well wait until then. I didn’t go last year but as it stands I’ll definitely be going this year.

I find it inconceivable that SNG have not at least had a conversation with Jansen since they are working together on the together trial. But the strive trial is the elephant in the room. If we are on it then do we even need Jansen ? It would seem to be one or the other.

Aether same as they are now ie buy / sell / hold. If we are to be on a platform trial eg Strive then the trial organisers will be ready when they are ready and this is not in SNG's control. Strive certainly wont be working to 21st Feb as a deadline or any other date.

Hi Ghia, who specifically are you referring to when you talk about the key players ? Regards.

I’m just wondering why they are hiring for a job whose role is “post regulatory approval” ? If we got on a new trail tomorrow it would be a year ( or more ) to do the trial, 6 months to get the data, maybe another 6 months to get the approvals. So we are hiring for a job that’s not even needed for 2 years ? Seems a bit strange.

Xvoilet SNG has enough cash in the bank to last until September, maybe they can eek out an extra few months if they are careful. So they have a bit of time, but not a lot of time. You would have thought they would want something sorting before the bank account hits empty, a fund raise for cash flow with no trial in place is not going to be a good look.

Well we know there needs to be a new trial, and RM has just told us that is is complex to arrange due to the multiple viruses covered. So I suppose it makes sense they might hire someone extra to help with this. is she helping design the trial, is the trial already design already done and she is more involved in logistics once its up and running, who knows ?!? It doesn't mean we definitely are on a trial, and more importantly it doesn't answer how the trial will be paid for. So I see this as a non event, it literally tells us nothing.

Just google it:

On Sunday, Italy’s Chiesi said it would acquire Amryt Pharma for $1.25 billion upfront, agreeing to pay a 107% per share premium over the closing price of rare disease drug developer’s stock at the end of last week.

AstraZeneca will initiate a tender offer to acquire all of CinCor’s outstanding shares for a price of $26 per share in cash at closing, The upfront cash portion of the consideration represents a transaction value of approximately $1.3bn and a 121% premium over CinCor’s closing market price on 06 January 2023.

There you go doc 83 old buddy old pal.

Sorry 30M not 15M

I think that is the point the J & J guy is trying to make...... why would you pay £200M for a company with a MCAP of £15M ? Makes no sense and it makes it hard to get deals done.

https://www.biopharmadive.com/news/johnson-johnson-deals-biotech-valuation-earnings/634371/

Interesting quote here from Johnson and Johnson ( ie Jansen ), “The market’s a little bit funny. The volatility actually doesn’t help for a conducive M&A environment right now because you have potential sellers holding on to 52-week highs or all-time highs, which, quite frankly, aren’t too distant in the rearview mirror,”

He could easily be talking about us there !

I note all the deals done so far at the JP Morgan conference have been for basically double the MCAP valuations of the companies bought. Whose up for a sale of SNG for 30p ! Not me !